Table 1.

Relevant results on the interaction between dyslipidemia and other metabolic disturbances and thrombosis or other factors in myeloproliferative neoplasm

Ref.	Study sample	MPN subtypes	Main findings
Pedersen et al[33]	116728	Not specified	↓ Apolipoprotein A1 (HR = 1.59, 95%CI: 1.22-2.08; P < 0.001) = ↑ risk of MPNs
Pedersen et al[33]	116728	Not specified	↓ HDL-C (HR = 1.66, 95%CI: 1.22-2.26; P < 0.001) = ↑ risk of MPNs
Zhang et al[34]	1537	PV, ET, PMF	↑ Rates of dyslipidemia in MPNs individuals with thrombotic events vs thrombosis-free (62.1% vs 37.9%; P < 0.0001)
García-Fortes et al[36]	668	PMF, post-PV MF, post-ET MF	Negative association of survival and dyslipidemia in MF (HR = 4.65, 95%CI: 3.11-6.95; P < 0.001)
Stein et al[38]	164	PV, ET, PMF	Association of dyslipidemia and history of thrombotic events (OR = 2.31, 95%CI: 1.00-5.34; P = 0.05) in JAK2V617F-positive MPNs
Gu et al[39]	567	PV	CVRFs (including dyslipidemia) = predictors of thrombosis after MPN diagnosis (HR = 4.22, 95%CI: 2.00-8.92; P < 0.001)
Horvat et al[40]	258	PV, ET, PMF	Association between dyslipidemia and vascular events (OR = 3.5, 95%CI: 1.8-6.8; P < 0.001), arterial thrombosis (OR = 4.1, 95%CI: 2.0-8.3; P < 0.001), venous thrombosis (OR = 1.5, 95%CI: 0.5-4.5; P = 0.330), arterial thrombosis in ET (OR = 4.5, 95%CI: 1.6-12.6; P = 0.006), and PMF (OR = 6.1, 95%CI: 1.1-33.6; P = 0.046)
Furuya et al[41]	580	ET	↑ TG positively associated with thrombotic events in ET (HR = 3.530, 95%CI: 1.630-7.643; P < 0.001)
Furuya et al[41]	580	ET	LDL-C concentrations marginally associated with vascular events in ET (HR = 2.191, 95%CI: 0.966-4.971; P = 0.061)
Furuya et al[41]	580	ET	↑ TG = only CVRF associated with thrombosis in ET (HR = 3.364, 95%CI: 1.541-7.346; P = 0.002)
Furuya et al[41]	580	ET	TG ≥ 106.19 mg/dL = ↓ thrombosis-free survival in ET (HR = 2.592; P = 0.026)
Košťál et al[42]	1142	PV, ET, PMF	Hypertriglyceridemia not hypercholesterolemia = RF for cerebrovascular events (HR = 1.734, 95%CI: 1.162-2.586; P = 0.008)
Košťál et al[42]	1142	PV, ET, PMF	Hypertriglyceridemia and not hypercholesterolemia = RF for cerebrovascular events in MPNs without cytoreductive treatment (OR = 2.265, 95%CI: 1.188-4.318; P = 0.015)
Hashimoto et al[45]	1152	ET	Hypertriglyceridemia predicts thrombosis-free survival (HR = 3.018, 95%CI: 1.644-5.540; P < 0.001)
Hashimoto et al[45]	1152	ET	↑ LDL-C marginally predicts thrombosis-free survival (HR = 1.722, 95%CI: 0.979-3.029; P = 0.059)
Benevolo et al[47]	816	PV	overweight/obese PV = ↓ post-PV MF rates (HR = 0.38, 95%CI = 0.15-0.94; P = 0.04)
Benevolo et al[47]	816	PV	overweight/obese PV = ↑ survival rates (HR = 0.42, 95%CI: 0.18-0.97; P = 0.04)
Christensen et al[48]	3114	PV, ET, PMF	obesity + MPNs = ↑ symptom burden & ↓ QoL vs normal-weight MPNs

CI: Confidence interval; CVRFs: Cardiovascular risk factors; ET: Essential thrombocythemia; HDL-C: High-density lipoprotein cholesterol; HR: Hazard ratio; MF: Myelofibrosis; MPNs: Myeloproliferative neoplasms; OR: Odds ratio; PMF: Primary myelofibrosis; PV: Polycythemia vera; QoL: Quality of life; RF: Risk factor; ↑ increased/elevated; ↓: Reduced/decreased.